Abstract
Background As one of the World Health Organization (WHO) End Tuberculosis (TB) Strategy is to reduce the proportion of TB affected families that face catastrophic costs to 0% by 2020. This systematic review and meta-analysis aimed to estimate the pooled proportion of TB affected households who face catastrophic cost.
Method A search of the online database through September 2020 was performed. A total of 5114 articles were found, of which 29 articles got included in quantitative synthesis. Catastrophic cost is defined if total cost related to TB exceeded 20% of annual pre-TB household income. R software was used to estimate the pooled proportion at 95% confidence intervals (CIs) using the fixed/random-effect models.
Result The proportion of patients faced catastrophic cost was 43% (95% CI 34-52, I2 = 99%); 32% (95% CI 29 – 35, I2 = 70%) among drug sensitive, and 80% (95% CI 74-85, I2 = 54%) among drug resistant, and 81% (95%CI 78-84%, I2 = 0%) among HIV patients. Regarding active versus passive case finding the pooled proportion of catastrophic cost was 12% (95% CI 9-16, I2 = 95%) versus 42% (95% CI 35-50, I2 = 94%). The pooled proportion of direct cost to the total cost was 45% (95% CI 39-51, I2 = 91%). The pooled proportion of patients facing catastrophic health expenditure (CHE) at cut of point of 10% of their yearly income was 45% (95% CI 35-56, I2 = 93%) while at 40% of their capacity to pay was 63% (95% CI 40-80, I2 = 96%).
Conclusion Despite the ongoing efforts, there is a significant proportion of patients facing catastrophic cost, which represent a main obstacle against TB control.
PROSPERO registration CRD42020221283
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partially funded by WHO-TDR (SGS 20-28)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: ramy_ghazy{at}alexu.edu.eg, Email: ehabelrewany{at}alexu.edu.eg, Email: h.elsaeh{at}uot.edu.ly, E.mail: mri.shaimaa.m.informatics18{at}alexu.edu.eg, Email: Hiph.eabdellatif{at}alexu.edu.eg, E.mail: hiph.amiraelzorkany{at}alexu.edu.eg, E.mail: Nardine_zarif{at}yahoo.com, E.mail: heba_khidr{at}yahoo.com, Email: samarabdelhafeez.epid{at}gmail.com
Data Availability
all data are available.